Tests a pharmacist-led care plan for people with type 2 diabetes

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes whose HbA1c is not yet under 7.0% (53 mmol/mol). It tests a pharmacist-led diabetes care service.

Age

18 years or older

Sex

All sexes can join

Disease stage

Type 2 diabetes that is not at the HbA1c target of under 7.0% (53 mmol/mol)

Biomarker or test result

HbA1c of 7.0% (53 mmol/mol) or higher (not reaching the target of under 7.0% (53 mmol/mol))

Main reasons for not taking part

• Type 1 diabetes, gestational diabetes or other diabetes that is not type 2
• Pregnant people
• HbA1c already under 7.0% (53 mmol/mol)
• Limited life expectancy, frailty or no awareness of low blood sugar
• Unable to give consent or unwilling to attend follow-up visits

The registry criteria, word for word

What the trial wants to find out

As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, but need to give people more support to help them manage their diabetes. Pharmacists are respected health care professionals who are often easier to see that doctors and can help people with diabetes to stay as healthy as possible.

The 2 groups in the trial

• Pharmacist-led care pathwayTreatment being tested

  Participants in the intervention arm will receive the care using a shared decision-making pharmacist care pathway approach designed to guide type 2 diabetes management to achieve target A1C levels and reduce the risk of diabetes-related complications. The pharmacist care pathway is modelled after the Canadian Diabetes Association Guidelines. This pathway (tool) will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to achieve target A1C levels and reduce the risk of diabetes-related complications. This will occur through follow-ups every 6 weeks for six months duration.

  Treatment: Pharmacist-led diabetes care pathway

• Usual CareNo study treatment, for comparison

  The control group will involve facilitated relay of information to participants' family physician or nurse practitioner. Participants in the control group will have their pharmacist collect information informing the patient's current diabetes control. Participants will then be given a letter that contains their A1C value, and they will be advised to present it to their family physician or nurse practitioner. No specific suggestions for diabetes management will be detailed in the letter. In the case where the patient does not have a family physician or nurse practitioner, they will be referred to a physician walk-in clinic. A follow-up appointment will be booked for all participants in the control group at 3-months to discuss dietary and lifestyle interventions in the management of type 2 diabetes to maintain participant interest in the study and again at 6-months' time for a final visit.